DDInter393 DDInter899
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Clarithromycin {u} (Compound) resembles {v} (Compound) Troleandomycin
Clarithromycin {u} (Compound) resembles {v} (Compound) Josamycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
Clarithromycin {u} (Compound) upregulates {v} (Gene) SLC25A14
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Clarithromycin {u} (Compound) downregulates {v} (Gene) TIMM9
Clarithromycin {u} (Compound) causes {v} (Side Effect) Gingival bleeding
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amoxicillin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Clarithromycin (Compound) resembles Troleandomycin (Compound)
Clarithromycin (Compound) resembles Josamycin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Clarithromycin (Compound) binds ABCB1 (Gene)
Clarithromycin (Compound) upregulates SLC25A14 (Gene)
Clarithromycin (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Clarithromycin (Compound) downregulates TIMM9 (Gene)
Clarithromycin (Compound) causes Gingival bleeding (Side Effect)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amoxicillin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol